These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9122737)

  • 21. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
    van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
    J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
    Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
    Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
    Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
    J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
    Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of phase I clinical studies with topotecan.
    Rowinsky EK; Verweij J
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
    Sharma S; Kemeny N; Schwartz GK; Kelsen D; O'Reilly E; Ilson D; Coyle J; De Jager RL; Ducharme MP; Kleban S; Hollywood E; Saltz LB
    Clin Cancer Res; 2001 Dec; 7(12):3963-70. PubMed ID: 11751488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
    Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
    J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.
    Muggia F; Liebes L; Potmesil M; Hamilton A; Hochster H; Hornreich G; Sorich J; Downey A; Wasserstrom H
    Ann N Y Acad Sci; 2000; 922():178-87. PubMed ID: 11193893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I studies of nogitecan hydrochloride for Japanese.
    Kobayashi K; Hino M; Fukuoka M; Takeuchi K; Furuse K; Yoneda S; Hasegawa K; Noda K; Kinoshita H; Kimura I; Taguchi T; Kanamaru R; Horikoshi N; Niitani H
    Int J Clin Oncol; 2002 Jun; 7(3):177-86. PubMed ID: 12109520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan in the treatment of gynecologic cancer.
    Coleman RL; Miller DS
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
    J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.